Ahmed Alibrahim

Dr. Ahmed Alibrahim

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2022 in Cureus
Verified
Journal Article
Open access
AAAhmed Alibrahim
Ahmed Alibrahim
YAYousef M. Al-Saleh
Yousef M. Al-Saleh
TBThamer O Basahih
Thamer O Basahih
ABAbdullah R. Bukhari
Abdullah R. Bukhari
AAAbdullah A Alqahtani
Abdullah A Alqahtani
NANaif S. Albudayri
Naif S. Albudayri
The relationship between type 1 diabetes mellitus (T1DM) and other autoimmune diseases has been known; however, the actual prevalence in the adult population nor clinical symptoms has not been determined locally. We aim to determine the prevalence of associated autoimmune diseases (Hashimoto’s thyroiditis, celiac disease (CD), and adrenal insufficiency (AI)) and evaluate the most reporting symptoms and glycemic control assessment, as well as microvascular complications and hypoglycemia episodes. A cross-sectional study of 251 patients with T1DM at the diabetic clinic of King Abdulaziz Medical City in Riyadh (KAMC-RD), Saudi Arabia, was conducted. Autoimmune serologies including thyroid peroxidase (TPO) antibody and tissue transglutaminase IgA (tTG-IgA) antibody were checked with hormonal studies such as thyroid-stimulating hormone (TSH), morning serum cortisol, and short Synacthen test (SST) with duodenal biopsy results all were reviewed if present. Patients were directly interviewed to evaluate for the most common symptoms (including hypoglycemia episodes) for the preceding two weeks. Glycemic control was assessed by measuring glycated hemoglobin (HbA1c). Microvascular complications (i.e., nephropathy and retinopathy) were estimated by looking at the urine albumin/creatinine ratio (ACR) besides the ophthalmology’s visit notes. The mean age was 26.3 ± 7.7 years, and the mean duration of diabetes at the time of data collection was 12.2 ± 7.6 years, whereas the mean HbA1c was 8.9% ± 1.8%. The prevalence of hypothyroidism was 16.3%, and TPO positivity was discovered in 58.6% of the tested patients (n = 70) with equal prevalence among both genders (p = 0.685). tTG-IgA were noticed among 16.4% of the patients (n = 164) without significant difference among gender. Serum cortisol test was performed among 128 patients; 28.1% had suboptimal levels, and 5.5% were deficient. Only four patients (n = 15) had suboptimal responses after SST. Nervousness and anxiety (p < 0.001), fatigue with weakness (p = 0.018), weight gain (p = 0.017), and cold intolerance (p = 0.005) were noted, which were statistically significantly higher among females. Weight gain was statistically significantly higher among the age group of >30 years (p = 0.036). For microvascular complication screening, ACR was collected in 199 (79.2%) participants, with a mean of 27.7 ± 155.9 mg/mmol. Only 10 (5%) patients had microalbuminuria, and 16 (8%) had macroalbuminuria; it was correlated significantly with diabetes duration (p = 0.045). A total of 132 (52.8%) patients were seen by ophthalmology, 28 (21.4%) had nonproliferative diabetic retinopathy (NPDR), and 10 (7.6%) has proliferative diabetic retinopathy (PDR) that significantly correlated with the duration of diabetes (p = 0.027). During patient interviews, 187 (74.5%) reported symptomatic hypoglycemia events that correlated significantly with glycemic control (p = 0.029). Autoimmunity in Saudi adults with type 1 diabetes mellitus was significant with equal prevalence among both genders and age groups with no or slight difference. Clinical manifestations of autoimmunity were higher in women. Diabetes chronicity and poor glycemic control were the major complications; therefore, early glycemic control is advocated. Regular screening for autoimmunity and its complications is recommended for type 1 diabetic patients. Autoimmunity was found almost similar to previous literature.

19 July 2024 in Medicine
Verified
Journal Article
Open access
MMMoeber Mohammed Mahzari
Moeber Mohammed Mahzari
AAAbdulmalik M. Alanazy
Abdulmalik M. Alanazy
ZFZeeshan feroz
Zeeshan feroz
KAKhalid M. Almani
Khalid M. Almani
MAMeshari Ali Alghamdi
Meshari Ali Alghamdi
MBMotasim HY Badri
Motasim HY Badri
Liraglutide, a glucagon-like peptide 1 receptor agonist, effectively treats type 2 diabetes(T2D) by lowering glucose levels, suppressing glucagon release, and promoting insulin secretion. Liraglutide has been shown to reduce body weight and glycated hemoglobin (HbA1c) levels and improve cardiovascular outcomes. However, evidence regarding the association between liraglutide and diabetic retinopathy in the Middle East is insufficient. Therefore, this study aimed to investigate the characteristics and risk factors of diabetic retinopathy in patients with T2D treated with liraglutide in Saudi Arabia. This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh. Data collection included demographic information, retinopathy status, body mass index (BMI), and HbA1c level at baseline and follow-up after liraglutide use. The study included 181 patients with a mean age of 58.2 (9.8) years. Of these, 72.9% were females. At baseline, the median weight (interquartile range) was 88 (77–100) kg, diabetes duration was 19 (13–23.5) years, and HbA1c level was 9% (8–10%). Total of 69.6% were on insulin, 22.7% were on oral hypoglycemic agents, and 7.7% were on no other medications in addition to liraglutide. After a median of 2 years follow-up, both HbA1c level and weight decreased significantly (P < .001). Seventy-one of the 87 patients (81.6%) without retinopathy at baseline continued to show no retinopathy. Among patients with retinopathy at baseline, 25.5% showed improvement and 44.7% showed no change. In the multivariate binary mixed effect analysis, factors significantly associated with retinopathy were: use of insulin (odds ratio [OR]:2.68; 95% confidence interval [CI]: 1.18–6.09, P = .019), older age (OR:1.03; 95% CI: 1.00–1.06; P = .022), higher HbA1c level (OR:1.17; 95% CI: 1.02–1.34; P = .024), Hypertension (OR:2.56; 95% CI: 1.13–5.76; P=<.0001) and longer diabetes duration (OR:1.04; 95% CI: 1.00–1.08; P = .024). In conclusion, liraglutide use caused significant reductions in the HbA1c level and weight of patients with T2D. Most patients showed no change in retinopathy status after liraglutide use.

14 May 2022 in Cureus
Verified
Journal Article
Open access
WAWaleed Almutairi
Waleed Almutairi
AAAhmed Alibrahim
Ahmed Alibrahim
MAMamdouh Alanazi
Mamdouh Alanazi
It Is well known that abdominal pain during pregnancy has a broad differential diagnosis, which includes spontaneous adrenal hemorrhage (SAH), a rarely reported phenomenon in the literature, defined as an acute hemorrhage into the adrenal gland during pregnancy in the absence of a clear cause. Physicians should have a high suspicion for it due to the potentially life-threatening complications, as they present usually with a non-specific presentation. We present a case of symptomatic SAH in the third trimester of pregnancy that was successfully managed conservatively.

26 December 2025 in Medicine
Verified
Journal Article
Open access
FSFatemah Saleh Bin Saleh
Fatemah Saleh Bin Saleh
AAAhmed Alibrahim
Ahmed Alibrahim
AAAwad AlShahrani
Awad AlShahrani
AAAida Aldughaither
Aida Aldughaither
MMMoeber Mohammed Mahzari
Moeber Mohammed Mahzari
GAGhadah B. Alanazi
Ghadah B. Alanazi
Types 1 and 2 diabetes mellitus (T1DM and T2DM, respectively) are chronic conditions with distinct pathophysiological mechanisms and clinical manifestations. Dyslipidemia is a common complication in both types, contributing to increased cardiovascular risk. This study aimed to compare the demographic and laboratory characteristics of patients with T1DM and T2DM in Saudi Arabia. We conducted 2 different studies both are retrospective cross-sectional studies that involved 409 T2DM and 509 T1DM patients, respectively. Data were collected from electronic medical records. Clinical characteristics, including diabetes duration, body mass index, hemoglobin A1C levels, and lipid profiles, were analyzed. Statistical comparisons were conducted to identify significant differences between the 2 groups. Patients with T2DM were older (mean age, 58.93 years) than those with T1DM (mean age, 26.15 years). Additionally, substantial demographic differences were observed between the 2 groups. Compared with patients with T2DM, who had hemoglobin A1C levels between 7% to 9%, patients with T1DM had worse glycemic control, with 55.8% of them having such values. Patients with T2DM were more likely to have obesity (63.6%) than those with T1DM (21.8%). Compared with patients with T2DM, those with T1DM had lower triglyceride levels but higher mean low-density lipoprotein, high-density lipoprotein, and total cholesterol levels. A considerably larger proportion of individuals with T2DM had aberrant triglyceride and low high-density lipoprotein levels, indicating a higher incidence of dyslipidemia. Patients with T1DM and T2DM have different clinical characteristics and lipid abnormalities. Patients with T2DM are at higher risk of dyslipidemia and related cardiovascular complications. To reduce cardiovascular risk in patients with diabetes, customized therapies that concentrate on lipid management and glycemic control are necessary. To manage dyslipidemia, further studies are necessary to investigate the underlying mechanisms and develop efficient treatment plans.

3 June 2022 in Cureus
Verified
Journal Article
Open access
AAAwad AlShahrani
Awad AlShahrani
AAAhmed Alibrahim
Ahmed Alibrahim
MAMamdouh M. Alanazi
Mamdouh M. Alanazi
AOAamir Omair
Aamir Omair
MAMuatassem A Alsadhan
Muatassem A Alsadhan
MMMoeber Mohammed Mahzari
Moeber Mohammed Mahzari
Objective: Dyslipidemia is prevalent in adults living with type 1 diabetes, and it can worsen the presentation of microvascular complications such as retinopathy. This study aims to identify the pattern coupled with the frequency of dyslipidemia in diabetic adults who followed up at different clinics in King Abdulaziz Medical City, Riyadh, and evaluate the associations with demographic and clinical characteristics. Methods: A cross-sectional, retrospective chart review study of 514 adults with type 1 diabetes was conducted in a tertiary health care facility in the central region of Saudi Arabia. Demographics were retrieved by using the implemented electronic medical records. Fasting lipid profile, glycated hemoglobin (HbA1c), and thyroid-stimulating hormone (TSH) levels were checked for all subjects. Results: Five hundred and fourteen (514) subjects aged 18-65 years were studied (mean age: 26.1 ± 7.1 years). There were 318 (62%) females in the sample, and their mean age was significantly different from the mean age of males (p = 0.01). The mean duration of having diabetes was 12.8 ± 6.9 years. The prevalence of lipid abnormalities included abnormal low-density lipoprotein (LDL) (70%), hypercholesterolemia (23%), abnormal high-density lipoprotein (HDL) (8%), and hypertriglyceridemia (5%). Abnormal HDL was significantly higher in males than in females (p=<0.001). There were no statistically significant differences in the prevalence of other lipid abnormalities between the two genders and the age group < or ≥ 25 years. There was no statistically significant difference in the mean of the tested lipids levels between the two genders. One hundred and forty-three (143) (27.8%) patients had more than one abnormal lipid condition. A statistically significant difference was observed in the mean HbA1c between males and females (p=0.001). Otherwise, there was no significant association of lipid abnormalities with gender, age, diabetes duration, and weight. Conclusion: The most prevalent lipid abnormality was high LDL cholesterol. Nearly a third of the tested individuals had more than one lipid abnormality. Furthermore, poor glycemic control was linked to abnormal lipid profiles. Consequently, local programs must aim to screen and intervene early to delay and prevent future severe vascular complications related to non-treated dyslipidemia.

18 October 2023 in Cureus
Verified
Journal Article
Open access
PDF file
WAWaleed M. Almutairi
Waleed M. Almutairi
NANouf Alshamrani
Nouf Alshamrani
AAAhmed Alibrahim
Ahmed Alibrahim
Adrenal myelolipomas (AMs) are rare and benign neoplasms, consisting of adipose and mature hematopoietic tissue. They are commonly discovered incidentally with increased use of radiologic imaging. A small number of giant bilateral adrenal masses are reported, particularly in the setting of congenital adrenal hyperplasia (CAH). We report the case of a 36-year-old male with a history of CAH on steroids since childhood, self-discontinued shortly after diagnosis, presenting mainly with abdominal distension and pain besides infertility. Imaging revealed giant bilateral adrenal masses. Subsequently, he underwent bilateral adrenalectomy, and the surgical pathology report revealed myelolipomas measuring 39×17×8 cm on the left and weighing 4050 grams and 28×16×5 cm on the right and weighing 1702 grams. AMs are found to coexist with many other conditions such as Cushing’s syndrome, pheochromocytoma, and CAH. We discuss the association with high adrenocorticotropic hormone (ACTH) states and review the studies involving ACTH as a stimulator leading to myelolipomas. This case report highlights the proper history taking and biochemical evaluation for early detection and intervention to avoid catastrophic consequences.